Aspire Biopharma Holdings (ASBP) Debt Ratio (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Debt Ratio for 5 consecutive years, with 0.07 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Debt Ratio fell 96.86% year-over-year to 0.07 in Q1 2026; TTM through Mar 2026 was 0.07, a 96.86% decrease from a year earlier, with the FY2025 full-year figure at 2.32, down 97.79% from the prior year.
• Debt Ratio was 0.07 for Q1 2026 at Aspire Biopharma Holdings, down from 2.32 in the prior quarter.
• Over five years, Debt Ratio peaked at 104.92 in Q4 2024 and troughed at 0.02 in Q4 2023.
• A 4-year average of 13.2 and a median of 2.23 in 2025 frame the typical range for Debt Ratio.
• Across the five-year window, Debt Ratio surged 543909.19% in 2024 and sank 97.79% in 2025, its largest moves.
• Over 4 years, Debt Ratio stood at 0.02 in 2023, then surged by 543909.19% to 104.92 in 2024, then slumped by 97.79% to 2.32 in 2025, then plunged by 96.97% to 0.07 in 2026.
• The last three Debt Ratio figures came in at 0.07 (Q1 2026), 2.32 (Q4 2025), and 3.45 (Q3 2025), per Business Quant data.